ENSC vs. BCAB, ADAP, MBRX, CASI, QTTB, FNCH, PASG, RVPH, RLMD, and PMN
Should you be buying Ensysce Biosciences stock or one of its competitors? The main competitors of Ensysce Biosciences include BioAtla (BCAB), Adaptimmune Therapeutics (ADAP), Moleculin Biotech (MBRX), CASI Pharmaceuticals (CASI), Q32 Bio (QTTB), Finch Therapeutics Group (FNCH), Passage Bio (PASG), Reviva Pharmaceuticals (RVPH), Relmada Therapeutics (RLMD), and Promis Neurosciences (PMN). These companies are all part of the "pharmaceutical products" industry.
Ensysce Biosciences vs. Its Competitors
BioAtla (NASDAQ:BCAB) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.
BioAtla has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -88.76%. Ensysce Biosciences' return on equity of -167.23% beat BioAtla's return on equity.
Ensysce Biosciences has lower revenue, but higher earnings than BioAtla. Ensysce Biosciences is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.
BioAtla has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, Ensysce Biosciences has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.
In the previous week, Ensysce Biosciences had 2 more articles in the media than BioAtla. MarketBeat recorded 4 mentions for Ensysce Biosciences and 2 mentions for BioAtla. BioAtla's average media sentiment score of -0.37 beat Ensysce Biosciences' score of -0.47 indicating that BioAtla is being referred to more favorably in the media.
77.2% of BioAtla shares are owned by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are owned by institutional investors. 11.2% of BioAtla shares are owned by company insiders. Comparatively, 7.9% of Ensysce Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
BioAtla currently has a consensus target price of $5.00, indicating a potential upside of 1,292.76%. Given BioAtla's stronger consensus rating and higher probable upside, research analysts plainly believe BioAtla is more favorable than Ensysce Biosciences.
Summary
BioAtla beats Ensysce Biosciences on 10 of the 15 factors compared between the two stocks.
Get Ensysce Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENSC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ENSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Ensysce Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:ENSC) was last updated on 8/22/2025 by MarketBeat.com Staff